Yan Xu

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

Wanhong Zhao, Jie Liu, Baiyan Wang et al. · Journal of Hematology & Oncology · 2018 · 526 citations · Full text

Immunology, Immunodominance, Immunotherapeutics +19

Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)

Wanhong Zhao, Baiyan Wang, Lijuan Chen et al. · Journal of Hematology & Oncology · 2022 · 139 citations · Full text

Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Baiyan Wang, Wanhong Zhao, Jie Liu et al. · Blood · 2019 · 91 citations

Assessing the Risk of pH-Dependent Absorption for New Molecular Entities: A Novel <i>in Vitro</i> Dissolution Test, Physicochemical Analysis, and Risk Assessment Strategy

Neil Mathias, Yan Xu, Dhaval Patel et al. · Molecular Pharmaceutics · 2013 · 64 citations

Pharmaceutical Science, Chemical Contaminant, Risk Assessment Strategy +19

Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1–2 study

Toby A. Eyre, Anna Schuh, William G. Wierda et al. · The Lancet Haematology · 2021 · 60 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Oncology +8